Common SPINK-1 mutations do not predispose to the development of non-alcoholic fatty liver disease

Annals of Hepatology

Volumn 8, Issue 2, 2009, Pages 116-119

  Oruc, Nevin ^a   Ozutemiz, Omer ^a   Akarca, Ulus Salih ^a   Berdeli, Afig ^a   Ersoz, Galip ^a   Gunsar, Fulya ^a   Karasu, Zeki ^a   Ilter, Tankut ^a   Batur, Yucel ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Insulin resistance; Mutation; NAFLD; SPINK1

Indexed keywords

SERINE PROTEINASE INHIBITOR;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; EXON; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC RISK; HEPATOGRAPHY; HOMEOSTASIS; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MUTATIONAL ANALYSIS; NONALCOHOLIC FATTY LIVER; SEQUENCE ANALYSIS; SERINE PROTEINASE INHIBITOR KAZAL 1 GENE;

EID: 67650538600     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31788-0     Document Type: Article

References (19)

1. Siebler J, Galle PR, Weber MM. The gut-liver-axis: endotoxemia, inflammation, insulin resistance and NASH. J Hepatol 2008; 48: 1032-1034
2. Jiang J, Torok N. Nonalcoholic steatohepatitis and the metabolic syndrome. Metab Syndr Relat Disord 2008; 6: 1-7.
3. El-Zayadi AR. Hepatic steatosis: A benign disease or a silent killer. World J Gastroenterol 2008; 14(26): 4120-4126
4. Schweitz H, Vincent JP, Lazdunski M. Trypsin - pancreatic secretory inhibitor (Kazal inhibitor) interaction. Kinetic and thermodynamic properties. Biochemistry 1973; 12: 2841-2846
5. Masamune A, Kume K, Takagi Y, Kikuta K, Satoh K, Satoh A, Shimosegawa T. N34S mutation in the SPINK1 gene is not associated with alternative splicing. Pancreas 2007; 34: 423-428 (Pubitemid 46725783)
6. Teich N, Mössner J. Hereditary chronic pancreatitis. Best Pract Res Clin Gastroenterol 2008; 22: 115-130
7. Behrman SW, Fowler ES. Pathophysiology of chronic pancreatitis. Surg Clin North Am 2007; 87: 1309-1324
8. Schneider A, Suman A, Rossi L, Barmada MM, Beglinger C, Parvin S, Sattar S, et al. SPINK1/PSTI mutations are associated with tropical pancreatitis and type II diabetes mellitus in Bangladesh. Gastroenterology 2002; 123: 1026-1030
9. Hassan Z, Mohan V, Ali L, Allotey R, Barakat K, Faruque MO, Deepa R, et al. SPINK1 is a susceptibility gene for fibrocalculous pancreatic diabetes in subjects from the Southern Indian subcontinent. Am J Hum Genet 2002; 71: 964-968 (Pubitemid 135750528)
10. Jönsson P, Linder C, Genell S, Ohlsson K. Extrapancreatic origin of the pancreatic secretory trypsin inhibitor as an acute-phase reactant. Pancreas 1996; 12: 303-307 (Pubitemid 26092770)
11. Witt H, Luck W, Hennies HC, Classen M, Kage A, Lass U, Landt O, et al. Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis. Nat Genet 2000; 25: 213-216
12. Takamatsu S, Noguchi N, Kudoh A, Nakamura N, Kawamura T, Teramoto K, Igari T, et al. Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology 2008; 55: 609-614 (Pubitemid 351741512)
13. Abdelmalek MF, Liu C, Shuster J, Nelson DR, Asal NR. Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 1162-1169 (Pubitemid 44311647)
14. Adibi A, Janghorbani M, Shayganfar S, Amini M. First-degree relatives of patients with type 2 diabetes mellitus and risk of non-alcoholic Fatty liver disease. Rev Diabet Stud 2007; 4: 236-241
15. Boden G. Pathogenesis of type 2 diabetes. Insulin resistance. Endocrinol Metab Clin North Am 2001; 30: 801-815
16. Polonsky KS, Sturis J, Bell GL. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the P cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777-783 (Pubitemid 26089361)
17. Kido H, Yokogoshi Y, Katunuma N. A low-molecular-mass Kazal-type protease inhibitor isolated from rat hepatocytes is identical to rat pancreatic secretory trypsin inhibitor II. Purification and amino acid sequence. Eur J Biochem 1990; 188: 501-506 (Pubitemid 20109502)
18. Ohmachi Y, Murata A, Matsuura N, Yasuda T, Yasuda T, Monden M, Mori T, et al. Specific expression of the pancreatic-secretory-trypsin-inhibitor (PSTI) gene in hepatocellular carcinoma. Int J Cancer 1993; 55: 728-734 (Pubitemid 23354884)
19. Lee YC, Pan HW, Peng SY, Lai PL, Kuo WS, Ou YH, Hsu HC. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer 2007; 43: 736-744 (Pubitemid 46502912)